J&J Spent 130 Years Becoming a Household Name. Then It Spun the Household Out.

In 1886, fourteen people in New Brunswick, New Jersey set out to make one unglamorous thing: sterile dressings for surgery, so a wound stood a better chance of not killing the patient.¹ That was the whole company. A hundred and thirty-seven years later, the same company stood in front of the SEC and announced it was cutting loose the baby powder, the Band-Aids, the Listerine, the entire bathroom-cabinet portion of itself - the most recognizable products it owned - to keep the part almost no consumer could name.⁶¹⁰ J&J spent more than a century becoming a household name. Then it decided the household was a drag on the stock.

The official story is that J&J is a visionary diversified healthcare company that grew organically from gauze into one of the broadest portfolios in medicine. The truer story is plainer: J&J expanded mostly by buying its way into adjacent markets, and held each one only as long as it earned its keep. The expansion was never sacred. The shareholder return was.

The drugs came in a box marked 'acquired'

Here is the part the brand mythology quietly skips. J&J did not invent its way into the medicine business - it bought its way in. In 1959 it acquired McNeil and Cilag; in 1961 it bought Janssen Pharmaceutica, a Belgian firm founded only eight years earlier by Paul Janssen in the town of Beerse.³⁸ Those three purchases became the foundation of the entire pharmaceutical arm.³ Even Tylenol, the product most people assume J&J dreamed up, arrived inside McNeil, which had introduced it in 1955 as a children's elixir - four years before J&J acquired the company; J&J's move was to take it over the counter the following year.⁹ The pattern is the giveaway: this was not a company following an organic thread from dressings to drugs. It was a company with capital and a steady cash machine, methodically annexing the markets next door.

What made the whole sprawl coherent on paper was a single organizing word: health. By the 2000s J&J ran on three legs - Consumer, Pharmaceutical, and Medical Devices and Diagnostics⁴ - and its own filings insisted that its interest 'both historically and currently' had always been products related to human health and well-being.² Notice what that sentence does. It takes a baby-powder bottle and a cancer molecule and a hip implant and files them all under one tidy mission, so a financial decision can wear the costume of a calling. The unifying thread wasn't a technology or a customer. It was a category broad enough to justify almost anything.

Why decentralization made the empire so easy to dismantle

J&J ran on a principle it stated openly in its filings: decentralized management.² Each business was, in effect, its own company under a shared roof and a shared Credo. For decades this looked like a strength - it let an acquired drugmaker in Belgium run like a drugmaker and a baby-powder unit run like a consumer brand, without one strangling the other. But decentralization had a second, less-advertised property. If every leg already stands on its own, the legs come apart cleanly. The same architecture that made the conglomerate easy to assemble made it trivially easy to separate. You don't need to untangle a body when you've built it from modules.

So when management did the math in November 2021, the conclusion wrote itself: separate the Consumer Health business and let the parent chase the molecules.⁵ The mechanics were a multi-year, staged exit, not a single dramatic cut. Kenvue floated its IPO in May 2023, with J&J still holding roughly 90.9% immediately after,⁶ and only that July did the parent announce it would split off at least 80.1% of those shares to investors through a tax-free exchange offer.⁵ CNBC called it the largest restructuring in J&J's 135-year history.⁶ In other words: the company unwound the better part of a century of brand accumulation in stages careful enough to keep the tax bill near zero.

Wasn't this just a great company pruning to grow?

The fair objection is that the Kenvue split was textbook good management, not a confession that the diversification was hollow. Slow-growing consumer staples really do drag on a multiple; freeing the faster, higher-margin pharma and device businesses to be valued on their own terms is exactly what shareholders should want, and the spin was sold precisely as a refocusing on faster-growing divisions.⁶ All true. But that is the point, not the rebuttal. If the consumer business had been a strategic core - genuinely fused to the drug and device businesses - you could not have lifted it out cleanly, because the value would have lived in the seams between the segments. It came out cleanly because there were no seams. The 'health and well-being' umbrella that justified holding baby powder and oncology under one roof turned out to be a narrative, not a synergy. The honest read is that adjacency expansion and adjacency divestiture are the same discipline, run forward and then in reverse: hold a market while it pays, exit it when the capital is worth more somewhere next door.

Strip away the heritage photos and the Credo, and J&J's expansion beyond its core reads as something cooler and more durable than vision: a century of buying into the markets next door, organizing them under a word elastic enough to hold them all, and keeping each one exactly as long as it served the return. The dressings made the cash. The cash bought the drugs, the devices, the powder, the brands in every medicine cabinet in America. And when the powder and the brands grew slower than the molecules, the same arithmetic that assembled the empire took it apart. The company never expanded out of love for any of it. It expanded toward the return - and in 2023, the return pointed away from the very products that made J&J a name you could say at the kitchen table.